Home Cart Sign in  
Chemical Structure| 1177827-73-4 Chemical Structure| 1177827-73-4

Structure of AP-III-a4
CAS No.: 1177827-73-4

Chemical Structure| 1177827-73-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ENOblock is a small molecule which is the first, nonsubstrate analogue that directly binds to enolase and inhibits its activity (IC50=0.576 μM) and inhibit cancer cell metastasis in vivo.

Synonyms: ENOblock

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AP-III-a4

CAS No. :1177827-73-4
Formula : C31H43FN8O3
M.W : 594.72
SMILES Code : O=C(CC1=CC=C(C=C1)NC2=NC(NCC3CCCCC3)=NC(NCC4=CC=C(C=C4)F)=N2)NCCOCCOCCN
Synonyms :
ENOblock
MDL No. :MFCD28009373
InChI Key :MOVYITHKOHMLHC-UHFFFAOYSA-N
Pubchem ID :24012277

Safety of AP-III-a4

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
AP-III-a4 is a novel nonsubstrate analogue inhibitor of enolase, exhibiting an IC50 of 0.576 μM, making it relevant for cancer and diabetes research[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
PAMC-82 cells 10 or 20 μM 24 or 36 hours Inhibited ENO1 activity, reduced cell self-renewal, migration, and invasion capabilities, and increased sensitivity to cisplatin PMC7567818
SNU16 cells 10 or 20 μM 24 or 36 hours Inhibited ENO1 activity, reduced cell self-renewal, migration, and invasion capabilities, and increased sensitivity to cisplatin PMC7567818
UM-1 cells 0, 1, 2.5, 5 µM 48 hours AP-III-a4 inhibited ENO2 expression in a dose-dependent manner, but showed no inhibitory effect on ENO1 expression. PMC9806895
Cal27 cells 0, 1, 2.5, 5 µM 48 hours AP-III-a4 inhibited ENO2 expression in a dose-dependent manner, but showed no inhibitory effect on ENO1 expression. PMC9806895
BV-2 microglia 5 μM 24 hours ENOblock inhibits Rho A/ROCK II activation, reducing inflaμMation and neurodegeneration, and promotes neural repair PMC10075133
VSC4.1 motoneuron cells 5 μM 24 hours ENOblock reduces Cat X expression, protects neuronal cells, and promotes neural regeneration PMC10075133
NIH/3T3 fibroblasts 10 μM 48 hours ENOblock treatment reduced enolase activity PMC5341156
3T3-L1 pre-adipocytes 10 μM 48 hours ENOblock treatment increased nuclear localization of enolase PMC5341156
Huh7 hepatocytes 10 μM 48 hours ENOblock treatment increased nuclear localization of enolase PMC5341156
3T3-L1 white preadipocytes 10 µM 72 hours ENOblock treatment reduced mitochondrial membrane potential, suggesting it may promote mitochondrial uncoupling and thermogenesis through upregulation of Ucp-1 PMC6346001
Human hepatocytes 10 µM ENOblock treatment caused enolase to accumulate in the nucleus, suggesting it may function through nuclear translocation PMC6346001

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice UM-1 cell xenograft model Intraperitoneal injection 3 mg/kg/day Once daily for 10 days AP-III-a4 significantly inhibited the growth of UM-1 cell xenograft tumors, and no significant systemic toxicity was observed. PMC9806895
Mice IMQ-induced psoriasis-like model Topical application 20 mg/kg Every other day for 28 days To evaluate the effect of ENO1 inhibition or K17-Ser44 phosphorylation inhibition on psoriasis development, results showed that ENO1 inhibition or K17-Ser44 phosphorylation inhibition significantly alleviated the IMQ-induced psoriasis-like phenotype PMC10367554
Rats Spinal cord injury model Intravenous injection 1.5 mg/kg single injection ENOblock treatment significantly reduces inflammation following spinal cord injury, modulates metabolic hormones, reduces glial cell activation, and promotes neuroprotection PMC7483987
Sprague-Dawley rats acute spinal cord injury model intravenous injection 400mg Single dose ENOblock treatment significantly reduced NSE levels in serum and spinal cord tissues, decreased inflammatory cytokines/chemokines, and reduced glial activation. PMC5685929
Mice Type 2 diabetes model Intraperitoneal injection 100 mg/kg Daily or thrice-weekly for 10-12 weeks ENOblock treatment reduced blood glucose and LDL cholesterol levels, and decreased tissue fibrosis and apoptosis PMC5341156
Mice Diet-induced obesity model Intraperitoneal injection 100μg/kg twice, at 15 min and 24 h post-injury ENOblock treatment reduced weight gain, recovered body temperature, and improved metabolic and inflammatory parameters in obese mice PMC6346001

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.68mL

0.34mL

0.17mL

8.41mL

1.68mL

0.84mL

16.81mL

3.36mL

1.68mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories